Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women

Several clinical trials have demonstrated that antiretroviral (ARV) drugs, taken as pre-exposure prophylaxis (PrEP), can prevent HIV infection(1), with the magnitude of protection ranging from -49 to 86%(2–11). While these divergent outcomes are thought to be due primarily to product adherence(12),...

Descripción completa

Detalles Bibliográficos
Autores principales: McKinnon, Lyle R., Liebenberg, Lenine J., Yende-Zuma, Nonhlanhla, Archary, Derseree, Ngcapu, Sinaye, Sivro, Aida, Nagelkerke, Nico, Lerma, Gerardo Garcia, Kashuba, Angela D., Masson, Lindi, Mansoor, Leila E., Karim, Quarraisha Abdool, Abdool Karim, Salim S., Passmore, Jo-Ann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893390/
https://www.ncbi.nlm.nih.gov/pubmed/29480895
http://dx.doi.org/10.1038/nm.4506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893390/
https://www.ncbi.nlm.nih.gov/pubmed/29480895
http://dx.doi.org/10.1038/nm.4506

Ejemplares similares